| Business Summary | | Cerus
Corporation
is
developing
medical
systems
and
therapeutics
based
on
the
Company's
proprietary
Helinx
technology
for
inactivating
disease-causing
agents.
The
Company's
most
advanced
programs
are
focused
on
systems
to
inactivate
viruses,
bacteria
and
other
pathogens
in
platelets,
fresh
frozen
plasma
and
red
blood
cells
intended
for
transfusion.
The
Company's
technology
has
potential
applications
in
the
health
care
field
beyond
pathogen
inactivation
in
blood
components.
The
Company
has
collaboration
agreements
with
Baxter
Healthcare
Corporation,
the
Pharmaceutical
Division
of
Kirin
Brewery
Co.,
Ltd.
and
the
Consortium
for
Plasma
Science. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Cerus
Corp.
is
developing
medical
products
based
on
a
platform
technology
that
prevents
nucleic
acid
(DNA
and
RNA)
replication,
allowing
for
the
development
of
systems
to
inactivate
viruses,
bacteria
and
other
pathogens
in
blood
components.
For
the
six
months
ended
6/01,
revenues
totalled
$3
million,
up
from
$1.2
million.
Net
loss
rose
45%
to
$23.1
million.
Revenues
reflect
increased
development
agreements
and
government
grants.
Higher
loss
reflects
increased
R&D
expenditures. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| B. Cassin, 67 Chairman | -- | -- | Stephen Isaacs, 52 Pres,
CEO | $420K | -- | Gregory Schafer, 36 CFO,
VP-Fin. | 196K | $90K | John Hearst, Ph.D., 65 VP-
New Science Opportunities | 262K | -- | James Vaughn, 38 VP
of Marketing | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|